Abstract
There now exists an enhanced opportunity for urologists to continue to successfully identify, treat, and manage advanced prostate cancer patients in partnership with our medical oncology and radiation oncology colleagues. For urologists and their supporting staff who are dedicated to caring for patients with advanced prostate cancer, there are novel therapies that delay disease progression, maintain – and oftentimes improve – quality-of-life metrics, and prolong overall survival. These therapies are not unusually difficult to manage, nor are they too intimidating with regard to understanding their mechanisms of action and respective safety profiles. They provide the opportunity to improve and enhance patient care, as well as to further augment the urological role in both the academic and community multidisciplinary prostate cancer clinic.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: •• Of major importance
American Cancer Society. Cancer Facts and Figures 2013 [cited 2013 August 12]. Available from: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf.
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.
Solo K, Mehra R, Dhawan J, Valant J, Scher HI. Prevalence of prostate cancer (PC) clinical states (CS) in the United States: estimates using a dynamic progression model [Abstract]. J Clin Oncol. 2011;29.
TAXOTERE® (docetaxel) Injection Concentrate [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; 2012.
Fitzpatrick JM. Management of castration-resistant prostate cancer: a call to urologists. BJU Int. 2012;110:772–4.
ZYTIGA® (abiraterone acetate) Tablets [prescribing information]. Horsham, PA: Janssen Biotech Inc; 2012.
XTANDI® (enzalutamide) Capsules [prescribing information]. Northbrook, IL: Astellas Pharma US, Inc; 2012.
PROVENGE® (sipuleucel-T) Suspension [prescribing information]. Seattle, WA: Dendreon Corporation; 2011.
JEVTANA® (cabazitaxel) Injection [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; 2012.
XGEVA® (denosumab) Injection [prescribing information]. Thousand Oaks, CA: Amgen Inc; 2013.
Xofigo® (radium Ra 223 dichloride) Injection [prescribing information]. Wayne, NJ: Bayer Healthcare Pharmaceuticals Inc; 2013.
Sartor AO, Fitzpatrick JM. Urologists and oncologists: adapting to a new treatment paradigm in castration-resistant prostate cancer (CRPC). BJU Int. 2012;110:328–35.
Harrison MR, Wong TZ, Armstrong AJ, George DJ. Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer Manag Res. 2013;5:1–14.
Cookson MS, Roth BJ, Dahm P, et al. Castration-resistant prostate cancer: AUA guideline. J Urol. 2013.
Nilsson S, Strang P, Aksnes AK, et al. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer. 2012;48:678–86.
Logothetis CJ, Basch E, Molina A, et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol. 2012;13:1210–7.
ZOMETA® (zoledronic acid) Injection [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012.
Eastham JA. Bone health in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2007;177:17–24.
Srinivas S, Colocci N. Bone related events in high risk prostate cancer. J Urol. 2006;176:S50–4.
Body JJ. Prevention and treatment of side-effects of systemic treatment: bone loss. Ann Oncol. 2010;21 Suppl 7:vii180–5.
LUPRON DEPOT® (leuprolide acetate) [prescribing information]. North Chicago, IL: Abbott Laboratories; 2013.
FIRMAGON® (degarelix for injection) [prescribing information]. Parsippany, NJ: Ferring Pharmaceuticals Inc.; 2013.
Bagrodia A, Diblasio CJ, Wake RW, Derweesh IH. Adverse effects of androgen deprivation therapy in prostate cancer: current management issues. Indian J Urol. 2009;25:169–76.
Taplin SH, Rodgers AB. Toward improving the quality of cancer care: addressing the interfaces of primary and oncology-related subspecialty care. J Natl Cancer Inst Monogr. 2010;2010:3–10.
CASODEX® (bicalutamide) Tablet [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2009.
Compliance with Ethics Guidelines
Conflict of Interest
Dr. Neal Shore has served as a consultant for and performed research for Amgen, Astellas, Algeta, Bayer, Dendreon, Janssen, Millennium, Medivation, Sanofi, Pfizer, BN ImmunoTherapeutics, and Orion. Dr. Shore is a section editor for Current Urology Reports.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is part of the Topical Collection on Prostate Cancer
Rights and permissions
About this article
Cite this article
Shore, N. Management of Advanced Prostate Cancer – Role of the Urologist. Curr Urol Rep 15, 419 (2014). https://doi.org/10.1007/s11934-014-0419-0
Published:
DOI: https://doi.org/10.1007/s11934-014-0419-0